Article
Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy.
Cell reports - 16 Feb 2021
Chen Ran, Okeyo-Owuor Theresa, Patel Riddhi M, Casey Emily B, Cluster Andrew S, Yang Wei, Magee Jeffrey A
Abstract excerpt
The myeloid tumor suppressor KMT2C is recurrently deleted in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), particularly therapy-related MDS/AML (t-MDS/t-AML), as part of larger chromosome 7 deletions. Here, we show that KMT2C deletions convey a selective advantage to hematopoietic stem cells (HSCs) after chemotherapy treatment that may precipitate t-MDS/t-AML. Kmt2c deletions markedly enhance...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.